Headlines about Curis (NASDAQ:CRIS) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.8323381664511 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Curis Announces Pricing of Public Offering of Common Stock – GlobeNewswire (press release) (globenewswire.com)
- Trending Stocks- Curis, Inc. (NASDAQ:CRIS), Teladoc, Inc. (NYSE:TDOC), QuickLogic Corporation (NASDAQ:QUIK) – Market Breaking Point (press release) (journalfinance.net)
- Curis, Inc. (NASDAQ:CRIS) – Simple Moving Averages under Consideration – The Investor Guide (wallstreetnews24.com)
- Curis prices stock offering but doesn’t disclose price (seekingalpha.com)
Curis (NASDAQ CRIS) traded down 6.52% on Friday, reaching $1.72. The company’s stock had a trading volume of 1,455,935 shares. The firm’s 50 day moving average price is $1.82 and its 200-day moving average price is $2.13. Curis has a 52 week low of $1.47 and a 52 week high of $3.72. The company’s market capitalization is $247.47 million.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The company had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. During the same quarter last year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. On average, equities analysts predict that Curis will post ($0.40) EPS for the current year.
CRIS has been the subject of several recent research reports. BidaskClub upgraded Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. ValuEngine cut Curis from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $5.50.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with our FREE daily email newsletter.